This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schrijvers, B. F. Articles by Flyvbjerg, A. Search for Related Content PubMed PubMed Citation Articles by Schrijvers, B. F. Articles by Flyvbjerg, A.

From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines

Medical Department M (B.F.S., A.F.), Medical Research Laboratories, Institute of Experimental Clinical Research, Aarhus University Hospital, DK-8000 Aarhus, Denmark; and Renal Unit (B.F.S., A.S.D.V.), Department of Internal Medicine, Gent University Hospital, B-9000 Gent, Belgium

Correspondence: Address all correspondence and requests for reprints to: Allan Flyvbjerg, M.D., D.M.Sc., Medical Department M/Medical Research Laboratories, Clinical Institute, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark. E-mail: allan.flyvbjerg{at}dadlnet.dk

At present, diabetic kidney disease affects about 15–25% of type 1 and 30–40% of type 2 diabetic patients. Several decades of extensive research has elucidated various pathways to be implicated in the development of diabetic kidney disease. This review focuses on the metabolic factors beyond blood glucose that are involved in the pathogenesis of diabetic kidney disease, i.e., advanced glycation end-products and the aldose reductase system. Furthermore, the contribution of hemodynamic factors, the renin-angiotensin system, the endothelin system, and the nitric oxide system, as well as the prominent role of the intracellular signaling molecule protein kinase C are discussed. Finally, the respective roles of TGF-ß, GH and IGFs, vascular endothelial growth factor, and platelet-derived growth factor are covered. The complex interplay between these different pathways will be highlighted. A brief introduction to each system and description of its expression in the normal kidney is followed by in vitro, experimental, and clinical evidence addressing the role of the system in diabetic kidney disease. Finally, well-known and potential therapeutic strategies targeting each system are discussed, ending with an overall conclusion.

This article has been cited by other articles:

				M. Iglarz, C. Binkert, K. Morrison, W. Fischli, J. Gatfield, A. Treiber, T. Weller, M. H. Bolli, C. Boss, S. Buchmann, et al. Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 736 - 745. [Abstract] [Full Text] [PDF]

				W.-Y. So, Y. Wang, M. C.Y. Ng, X. Yang, R. C.W. Ma, V. Lam, A. P.S. Kong, P. C.Y. Tong, and J. C.N. Chan Aldose Reductase Genotypes and Cardiorenal Complications: An 8-year prospective analysis of 1,074 type 2 diabetic patients Diabetes Care, November 1, 2008; 31(11): 2148 - 2153. [Abstract] [Full Text] [PDF]

				X. Shi, H. Qu, M. Kretzler, and C. Wu Roles of PINCH-2 in regulation of glomerular cell shape change and fibronectin matrix deposition Am J Physiol Renal Physiol, July 1, 2008; 295(1): F253 - F263. [Abstract] [Full Text] [PDF]

				X. Y. Shi, F. F. Hou, H. X. Niu, G. B. Wang, D. Xie, Z. J. Guo, Z. M. Zhou, F. Yang, J. W. Tian, and X. Zhang Advanced Oxidation Protein Products Promote Inflammation in Diabetic Kidney through Activation of Renal Nicotinamide Adenine Dinucleotide Phosphate Oxidase Endocrinology, April 1, 2008; 149(4): 1829 - 1839. [Abstract] [Full Text] [PDF]

				C. Granier, K. Makni, L. Molina, B. Jardin-Watelet, H. Ayadi, and F. Jarraya Gene and protein markers of diabetic nephropathy Nephrol. Dial. Transplant., March 1, 2008; 23(3): 792 - 799. [Full Text] [PDF]

				A. Dixon and C. Maric 17beta-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-beta protein expression and signaling Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1678 - F1690. [Abstract] [Full Text] [PDF]

				J.-S. Huang, L.-Y. Chuang, J.-Y. Guh, Y.-J. Huang, and M.-S. Hsu Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells Am J Physiol Renal Physiol, October 1, 2007; 293(4): F1072 - F1082. [Abstract] [Full Text] [PDF]

				M. Keck, M. J. Romero-Aleshire, Q. Cai, P. B. Hoyer, and H. L. Brooks Hormonal status affects the progression of STZ-induced diabetes and diabetic renal damage in the VCD mouse model of menopause Am J Physiol Renal Physiol, July 1, 2007; 293(1): F193 - F199. [Abstract] [Full Text] [PDF]

				K. Ekstrom, J. Salemyr, I. Zachrisson, C. Carlsson-Skwirut, E. Ortqvist, and P. Bang Normalization of the IGF-IGFBP Axis by Sustained Nightly Insulinization in Type 1 Diabetes Diabetes Care, June 1, 2007; 30(6): 1357 - 1363. [Abstract] [Full Text] [PDF]

				K. Y. Jung, K. Chen, M. Kretzler, and C. Wu TGF-beta1 Regulates the PINCH-1-Integrin-Linked Kinase-{alpha}-Parvin Complex in Glomerular Cells J. Am. Soc. Nephrol., January 1, 2007; 18(1): 66 - 73. [Abstract] [Full Text] [PDF]

				L.-Y. Chuang, J.-Y. Guh, K.-A. Wang, Y.-J. Huang, and J.-S. Huang Role of Nitric Oxide in High Glucose-Induced Mitogenic Response in Renal Fibroblasts Mol. Endocrinol., October 1, 2006; 20(10): 2548 - 2558. [Abstract] [Full Text] [PDF]

				S. M Marshall and A. Flyvbjerg Prevention and early detection of vascular complications of diabetes. BMJ, September 2, 2006; 333(7566): 475 - 480. [Full Text] [PDF]

				T. Samikkannu, J. J. Thomas, G. J. Bhat, V. Wittman, and T. J. Thekkumkara Acute effect of high glucose on long-term cell growth: a role for transient glucose increase in proximal tubule cell injury Am J Physiol Renal Physiol, July 1, 2006; 291(1): F162 - F175. [Abstract] [Full Text] [PDF]

				J. Ortmann, P. C. Nett, J. Celeiro, R. Hofmann-Lehmann, L. Tornillo, L. M. Terracciano, and M. Barton Downregulation of renal endothelin-converting enzyme 2 expression in early autoimmune diabetes. Experimental Biology and Medicine, June 1, 2006; 231(6): 1030 - 1033. [Abstract] [Full Text] [PDF]

				P. Katavetin, T. Miyata, R. Inagi, T. Tanaka, R. Sassa, J. R. Ingelfinger, T. Fujita, and M. Nangaku High Glucose Blunts Vascular Endothelial Growth Factor Response to Hypoxia via the Oxidative Stress-Regulated Hypoxia-Inducible Factor/Hypoxia-Responsible Element Pathway J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1405 - 1413. [Abstract] [Full Text] [PDF]

				L. J N Jensen, L. Denner, B. F Schrijvers, R. G Tilton, R. Rasch, and A. Flyvbjerg Renal effects of a neutralising RAGE-antibody in long-term streptozotocin-diabetic mice. J. Endocrinol., March 1, 2006; 188(3): 493 - 501. [Abstract] [Full Text] [PDF]

				B. F. Schrijvers, A. Flyvbjerg, R. G. Tilton, N. H. Lameire, and A. S. De Vriese A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat Nephrol. Dial. Transplant., February 1, 2006; 21(2): 324 - 329. [Abstract] [Full Text] [PDF]

				R. Zent and A. Pozzi Antiangiogenic Therapy in Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 325 - 327. [Full Text] [PDF]

				J. M. Bohlender, S. Franke, G. Stein, and G. Wolf Advanced glycation end products and the kidney Am J Physiol Renal Physiol, October 1, 2005; 289(4): F645 - F659. [Abstract] [Full Text] [PDF]